Last reviewed · How we verify
Oral PF-07081532 and IV [14C]PF-07081532 (oral-pf-07081532-and-iv-14c-pf-07081532)
Oral PF-07081532 and IV [14C]PF-07081532 (generic name: oral-pf-07081532-and-iv-14c-pf-07081532) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | oral-pf-07081532-and-iv-14c-pf-07081532 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral PF-07081532 and IV [14C]PF-07081532 CI brief — competitive landscape report
- Oral PF-07081532 and IV [14C]PF-07081532 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Oral PF-07081532 and IV [14C]PF-07081532
What is Oral PF-07081532 and IV [14C]PF-07081532?
Oral PF-07081532 and IV [14C]PF-07081532 (oral-pf-07081532-and-iv-14c-pf-07081532) is a pharmaceutical drug developed by Pfizer Inc..
Who makes Oral PF-07081532 and IV [14C]PF-07081532?
Oral PF-07081532 and IV [14C]PF-07081532 is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Oral PF-07081532 and IV [14C]PF-07081532?
oral-pf-07081532-and-iv-14c-pf-07081532 is the generic (nonproprietary) name of Oral PF-07081532 and IV [14C]PF-07081532.
What development phase is Oral PF-07081532 and IV [14C]PF-07081532 in?
Oral PF-07081532 and IV [14C]PF-07081532 is in Phase 1.